跳至主要内容
临床试验/NL-OMON50135
NL-OMON50135尚未招募不适用

Cardiomyopathy and heart failure risk after treatment for Hodgkin lymphoma or aggressive B cell non-Hodgkin lymphoma - CRYSTAL case-control

ederlands Kanker Instituut0 个研究点目标入组 800 人开始时间: 待定最近更新:
适应症

试验速览

阶段
不适用
状态
尚未招募
发起方
入组人数
800

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 至 99(—)

入选标准

  • All lymphoma survivors who meet the inclusion criteria of the P11CHT study or
  • the CRYSTAL cohort study are eligible for the CRYSTAL case-control study. The
  • most important inclusion criteria for the P11CHT and CRYSTAL cohort study are:
  • * Diagnosis of Hodgkin's lymphoma (P11CHT) or aggressive B-cell non-Hodgkin's
  • lymphoma (CRYSTAL cohort)
  • * Treatment for the lymphoma between 1965 and 2005 (P11CHT) or between 1989 and
  • 2012 (CRYSTAL cohort)
  • * Age at diagnosis <51 years (P11CHT) or <61 years (CRYSTAL cohort)
  • * Still alive at least 5 years after primary lymphoma treatment

排除标准

  • * A history of (symptomatic) myocardial infarction, valvular heart disease,
  • cardiomyopathy or heart failure before lymphoma diagnosis
  • * Chemotherapy or immunotherapy for a primary malignancy before lymphoma
  • * Radiotherapy to the trunk before lymphoma diagnosis
  • * Myocardial infarction or *CTCAE grade 2 valvular heart disease prior to
  • diagnosis of cardiomyopathy or heart failure
  • * Insufficient understanding of the Dutch language (for survivors receiving the
  • questionnaire)

研究者

发起方
ederlands Kanker Instituut

相似试验